The seismic shift away from face-to-face meetings caused by the pandemic has given the pharmaceutical industry a fundamental challenge around engaging with clinical staff.
COVID-19 has been a catalyst for a huge amount of change across the pharmaceutical industry, acting as an accelerant for progress in its use of digital technology and prompting a reassessme
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte